Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1984-15-2
Molecular formula
CH6O6P2
Molecular weight
176 g/mol
Drug class
Bisphosphonate liganddiagnostic radiopharmaceutical precursor for technetium-99m skeletal imaging
Mechanism of action
Medronic acid (methylene diphosphonate, MDP) chelates technetium-99m after reconstitution of a radiopharmaceutical kit. The labelled complex has affinity for hydroxyapatite in bone and accumulates in proportion to regional blood flow and osteoblastic activity, allowing skeletal scintigraphy.
Indications / reported uses
Used as the active ligand in technetium Tc-99m medronate (Tc-99m MDP) kits for skeletal scintigraphy and imaging of areas of increased osteogenic activity. The diagnostic imaging agent is the technetium-labelled product, not unlabelled medronic acid alone.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Medronic Acid Environmental Risk Assessment (ERA) (the Medronic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.